Patients who progressed after first-line targeted therapy and second-line immunotherapy can be rechallenged with targeted therapy, as strengthened antitumor immunity might contribute to the success of rechallenge after exposure to ICIs.
In the absence of strong evidence in metastatic melanoma, switching to immunotherapy in the absence of PD with targeted therapy should not be regularly considered outside of clinical trials.
Stopping treatment is common in clinical practice after 2 years of treatment with anti-PD-1 therapy when a patient achieves a PR or has stable disease. However, there are numerous considerations for stopping therapy in patients who respond to ICIs, including long-term side effects.
Learn more about advanced-stage melanoma management strategies.
Editor's Recommendations
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Winston W. Tan. Fast Five Quiz: Metastatic Melanoma Treatment - Medscape - May 24, 2023.
Comments